Physician profile
Andra E Talaska
NPI 1336537877
$10,579.75
in general payments reported to CMS, 2019-2025
46 companies · $2,595 in 2025
The $2,595 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,252 · 2022: $2,297 · 2023: $1,732 · 2024: $1,704 · 2025: $2,595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,013 · Education: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,013.47 |
| Education | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,148.37 | 2021-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $1,059.26 | 2021-2025 | |
| Abbott Laboratories | $823.65 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Amplatzer Amulet |
| Amgen INC. | $656.16 | 2021-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $652.43 | 2021-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $647.31 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $540.14 | 2021-2024 | Xarelto |
| Pfizer INC. | $506.56 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $493.09 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $476.42 | 2021-2025 | Verquvo, Winrevair |
| Astrazeneca Pharmaceuticals LP | $473.91 | 2021-2025 | Farxiga, Brilinta, Andexxa |
| Novo Nordisk INC | $420.56 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Chiesi USA, INC. | $315.77 | 2021-2025 | Kengreal, Cleviprex |
| Actelion Pharmaceuticals US, INC. | $214.42 | 2021-2025 | Opsumit, Uptravi |
| Kowa Pharmaceuticals America, INC. | $213.69 | 2021-2023 | Livalo |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $202.25 | 2021-2025 | Onpattro |
| Boston Scientific Corporation | $175.26 | 2021-2025 | Watchman Flx |
| Kiniksa Pharmaceuticals International, Plc | $132.30 | 2024 | Arcalyst |
| Medtronic, INC. | $117.05 | 2023-2025 | Aurora Ev-Icd Mri Surescan, Concertotm |
| Daiichi Sankyo INC. | $103.52 | 2021-2025 | Injectafer |
| Esperion Therapeutics, INC. | $100.74 | 2021-2025 | Nexletol |
| Bridgebio Pharma, INC. | $94.16 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $93.74 | 2022-2023 | |
| Kiniksa Pharmaceuticals, LTD. | $89.82 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $69.76 | 2023-2024 | Inpefa |
| Cmp Pharma, INC. | $66.73 | 2022-2023 | Norliqva |
| Vital Connect, INC | $66.26 | 2024 | Vitalpatch Rtm |
| Abiomed | $63.62 | 2024-2025 | Impella |
| Amarin Pharma, INC. | $61.90 | 2021-2022 | |
| Atricure, INC. | $54.97 | 2021-2022 | |
| Scpharmaceuticals INC. | $47.31 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $46.84 | 2025 | Keveyis |
| Impulse Dynamics (USA) INC. | $38.91 | 2024 | Optimizer |
| Csl Behring | $37.17 | 2021 | |
| Cardiva Medical, INC. | $35.39 | 2025 | Optowire |
| Lundbeck LLC | $31.58 | 2021 | |
| Lilly USA, LLC | $30.05 | 2025 | Zepbound, Mounjaro |
| Angiodynamics, INC. | $26.99 | 2021 | |
| W. L. Gore & Associates, INC. | $23.54 | 2025 | Gore Cardioform Septal Occluder |
| Alexion Pharmaceuticals, INC. | $23.07 | 2021 | |
| Corcept Therapeutics | $22.17 | 2025 | Korlym |
| Irhythm Technologies, INC. | $20.81 | 2022 | |
| Philips North America LLC | $16.79 | 2025 | Extended Holter |
| Analog Devices INC. | $16.41 | 2024 | Sensinel Cpm Wearable |
| Bardy Diagnostics, INC. | $14.54 | 2022 | |
| Biotronik INC. | $14.36 | 2024 | Amvia Edge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andra Talaska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.